Clinical Trial Update: Safety and Pharmacokinetics of Multiple Rising Oral Doses of BI 224436 in Healthy Male Volunteers. [Phase 1]

View source ↗

Summary

A Phase 1 trial evaluating safety and pharmacokinetics of escalating oral doses of BI-224436 in healthy male volunteers has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• BI-224436

Snippet

Sponsor: Boehringer Ingelheim | Conditions: HIV Infections, Healthy | Phase 1 | Status: WITHDRAWN